PAI
Palo Alto Investors Portfolio holdings
AUM $470M
1-Year Return
2.57%
This Quarter Return
-5.28%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$525M
AUM Growth
-$120M
(-19%)
Cap. Flow
-$70.1M
Cap. Flow
% of AUM
-13.35%
Top 10 Holdings %
Top 10 Hldgs %
74.78%
Holding
46
New
3
Increased
9
Reduced
11
Closed
2
Top Buys
| 1 |
Agios Pharmaceuticals
AGIO
|
+$8.1M |
| 2 |
Dyne Therapeutics
DYN
|
+$3.49M |
| 3 |
NovoCure
NVCR
|
+$3.35M |
| 4 |
AnaptysBio
ANAB
|
+$3.29M |
| 5 |
Biogen
BIIB
|
+$2.02M |
Top Sells
| 1 |
Insmed
INSM
|
+$47M |
| 2 |
United Therapeutics
UTHR
|
+$15.6M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$15.4M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$5.38M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$2.79M |
Sector Composition
| 1 | Healthcare | 97.86% |
| 2 | Financials | 2.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
BioNTech
BNTX
$23.6B
| $2.3M | 0.44% |
25,206
| – | – |
|
|
BCYC
27
Bicycle Therapeutics
BCYC
$480M
| $2.11M | 0.4% |
248,934
| – | – |
|
28
Travere Therapeutics
TVTX
$2.11B
| $1.98M | 0.38% |
110,719
| – | – |
|
29
Taysha Gene Therapies
TSHA
$791M
| $1.97M | 0.38% |
1,419,468
+608,200
| +75% | +$845K |
|
30
Neurocrine Biosciences
NBIX
$14.2B
| $1.47M | 0.28% |
+13,334
| New | +$1.47M |
|
31
Nuvation Bio
NUVB
$1.12B
| $1.36M | 0.26% |
772,652
| – | – |
|
32
Aldeyra Therapeutics
ALDX
$294M
| $1.3M | 0.25% |
225,465
| – | – |
|
33
Karyopharm Therapeutics
KPTI
$52.7M
| $1.21M | 0.23% |
324,032
-3,101
| -0.9% | -$11.6K |
|
34
Aclaris Therapeutics
ACRS
$196M
| $1.19M | 0.23% |
776,028
+206,196
| +36% | +$315K |
|
35
Humana
HUM
$32.4B
| $1.05M | 0.2% |
3,985
| – | – |
|
36
Pyxis Oncology
PYXS
$137M
| $1.02M | 0.19% |
1,037,421
| – | – |
|
37
Stoke Therapeutics
STOK
$1.25B
| $837K | 0.16% |
125,861
| – | – |
|
38
VYNE Therapeutics
VYNE
$7.75M
| $704K | 0.13% |
445,434
| – | – |
|
39
Abeona Therapeutics
ABEO
$289M
| $518K | 0.1% |
108,865
| – | – |
|
40
UroGen Pharma
URGN
$837M
| $271K | 0.05% |
24,500
| – | – |
|
41
Instil Bio
TIL
$145M
| $194K | 0.04% |
11,165
| – | – |
|
|
AKTX
42
Akari Therapeutics
AKTX
$25.9M
| $181K | 0.03% |
146,024
| – | – |
|
43
Relmada Therapeutics
RLMD
$50.1M
| $134K | 0.03% |
495,146
| – | – |
|
44
Generation Bio
GBIO
$38.9M
| $60.9K | 0.01% |
15,048
| – | – |
|
45
Jasper Therapeutics
JSPR
$37.9M
| – | – |
-30,651
| Closed | -$655K |
|
|
NVRO
46
DELISTED
NEVRO CORP.
NVRO
| – | – |
-750,371
| Closed | -$2.79M |
|